Artelo Biosciences, Inc. · NASDAQ:ARTL
Artelo Biosciences — Investor Presentation (May 2018)
28 slides from Artelo Biosciences's investor presentation, May 30, 2018
Slide 1: Investor Presentation May 2018
US Phone: 760-943-1689 IRE Phone: +35314434604 E-mail: info@artelobio.com www.artelobio.com Artelo BIOSCIENCES Investor Presentation May 2018 Greg Gorgas, CEO
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this Artelo Biosciences presentation that are not historical facts are "forward-looking statements" subject to risks/uncertainties. ‘Such statements are based on current facts/analyses and other information that are based on forecasts of results, estimates of
Slide 3: Company Overview
Company Overview Artelo Biosciences Introduction Company: US Public (OTCOB: ARTL) Sector: Biopharmaceutical Focus: Endocannabinoid system modulation Therapeutic areas: Inflammation, Pain, Anorexia/Cachexia, Cancer, Cardiovascular diseases US Headquarters: San Diego, California European Hub: Dublin,
Slide 4: Investor Opportunity: Investment Highlights
Investor Opportunity x Investment Highlights Q Three key platforms it) Robust patent fortress @ Proven leadership team © Near-term catalysts ruil) High-growth sector Artelo ‘ BIOSCIENCES.
Slide 5: Leading Science
Leading Science Using ECS Modulation to Improve Healthcare Outcomes “Modulating the ECS activity may have therapeutic potential in almost all diseases affecting humans, including obesity/metabolic syndrome, diabetes and diabetic complications, neuro-degenerative, inflammatory, cardiovascular, liver,
Slide 6: Diverse Approach to Modulating the Endocannabinoid System
Diverse Approach to Modulating the Endocannabinoid System Phase 2 We are developing a pupdccctanasoe ova ART 27.13 [Arron cachexia pharmaceuticals that ialeadetapate address serious — >) medical conditions ART 12.11 . Our programs are based on multiple mechanisms to target ART 26.12 and modulate the
Slide 7: Shareholder Value
Shareholder Value Creating Value with Potential Best-in-Class Therapeutics el ee rea a - _ rams, GW Pharmaceuticals (GWPH) 1 Bhase 9 (C80) en’ Fe od 1 Commercialized are the foundation for 4 Phase t significant value creation 2 resi een oir nal es) in a high-growth sector Tee 4 CBD gelin 3 Phase 2 1
Slide 8: ART 27.13 High-Potency Dual Agonist
ART 27.13 Artelo BIOSCIENCES High-Potency Dual Ag
Slide 9: Cannabinoid Agonists for Anorexia and Cancer
igh-Potency Dual Agoni Cannabinoid Agonists for Anorexia and Cancer Multiple cannabinoid agonists are already approved in the US and some other major markets for the treatment of nausea and vomiting related to cancer chemotherapy Cannabinoid * Clinical studies with cannabinoid agonists Sensiti have
Slide 10: High-Potency Dual Agonist: Excellent Clinical Profile
High-Potency Dual Agonist Excellent Clinical Profile for Use in Anorexia and Cancer AZD1940 ‘Developed at AstraZeneca Potent peripherally restricted €B/CB, agonist (AZ12368920) +5 clinical trials conducted in pain ‘Administered orally in 205 humans and its safety, tolerabi pharmacokinetics and pharm
Slide 11: Dose and Exposure Dependent Weight Gain Demonstrated in Phase I Study
tency Dual Ag Dose and Exposure Dependent Weight Gain Demonstrated in Phase | Study Weight enn te Weight gain vs exposure on day 12 (MAD study, n=50) At the intended dose (125-250 pg), 25% of subjects experienced gaining 3% or greater of baseline body weight Data on fite. Side effect profile of ART2
Slide 12: Supportive Activity Data for CB1/CB2 Agonists as Anti-Tumor Agents
otency Dual Ag Supportive Activity Data for CB1/CB2 Agonists as Anti-Tumor Agents 140. CB, Effect CB, Effect 120. 100. g & ” ” 0 - 20 o sg 1 2 ol 1 i § ‘Win55,212-2( yM) JWH-O15( yM) Artelo BIOSCIENCES. = Synthetic cannabinoids have anti-tumor effects as a monotherapy = Effects are blocked by cannab
Slide 13: ART 12.11 Proprietary CBD Composition
ia ART 12.11 Artelo BIOSCIENCES Proprietary CBD Composition
Slide 14: Cannabidiol's Protection Challenge for Pharmaceutical Development
Cannabidiol’s Protection Challenge for Pharmaceutical Development Cannabidiol (CBD) is in the public domain Market exclusivity strategies used by others * Delivery method (proprietary patch, spray, ointment, chewing gum, etc.) = Derivative manipulation (change the molecule to create new chemical ent
Slide 15: Cannabidiol's Inherent Polymorphism Challenge for Drug Development
Cannabidiol’s Inherent Polymorphism Challenge for Drug Development = Polymorphism in pharmaceuticals refers to the ability of a solid material to exist in two or more crystalline forms Polymorphic forms typically differ in their physicochemical properties and exhibit differences in pharmacological p
Slide 16: ART12.11 Proprietary CBD Composition
ART:2.23 Proprietary CBD Composition Cannabidiol (CBD) Comparisons Active Pharmaceutical CBD Phytocannabinoid Isolate (Synthetic Cannabinoid Artelo’s Cocrystal Composition of Matter Patent Protection Pending Problematic Polymorphism Inherent Inherent None identified (monomorph) Expected Superioritie
Slide 17: ART26.12
Ai0.n
Slide 18: FABP5 Inhibitor: Next Generation Endocannabinoid Modulator
FABPS Ii Next Generation Endocannabinoid Modulator Highly-selective, highly-potent FABPs inhibitor S’ I QNY = Invented at Stony Brook University BR4«@ CK = Nearly $4M invested via NIH grants \\ - _ UNIVERSITY = Two promising applications: = Novel and exciting mechanism of modulating the endocannabin
Slide 19: FABPs and the Endocannabinoid System
FABPs Inhibitor FABPs and the Endocannabinoid System Anandamide Inactivation Pathway »., FABP Transporter and FAAH Drug Targets » Overexpression of FABPs increases the hydrolysis of anandamide (AEA) Presynaptic Neuron eras = FABPs inhibition decreases AEA hydrolysis “ se « FABPs inhibition increases
Slide 20: FABPs is a Validated Target for Cancer Drug Development
FABPs Inhibitor FABPs is a Validated Target for Cancer Drug Development Long chain fatty acids ¢ iz itty. <4 FABPS » FABP5 delivers fatty acids to the nucleus to activate PPARB/5 and PPARy @ Vaseularization = Activation induces cell growth, survival genes, and angiogenic factors VEGPRA Endothelial c
Slide 21: FABPs is Upregulated in Breast, Prostate, and Cervical Cancer
FABPS Inh FABPs is Upregulated in Breast, Prostate, and Cervical Cancer In cancer patients, FABP5 is upregulated, correlates with tumor grade, and is associated with poor prognosis B Tumor Grade 100% : 80% Genetic silencing of FABPS is anti-tumor E 50% 9.0036, AL 2000 P=0.04 S 40% € 18004 wr é E 160
Slide 22: FABPs Inhibitor Decreases Tumor Growth in Prostate Cancer Model
FABPs Inhibitor FABPs Inhibitor Decreases Tumor Growth in Prostate Cancer Model ‘SBFI126 = ART26.12 —e—Control(PBS) == SBF126(from day 7) te SBF126(from day 1) + 6 9 13,9 17° 21 24 28 31 Days Inhibitor SBFI26 suppresses the malignant progression of castration- resistant PC3-M cells by competitively
Slide 23: Artelo Biosciences
Artelo BIOSCIENCES
Slide 24: Company Leadership: Proven Leadership
Company Leadershi Proven Leadership MANAGEMENT Biogen Idec, Chiron, Cetus, Upjohn Pfizer, Ligand, Biogen HSBC, Driver & Labour Recruit, Nursing Station Artelo BIOSCIENCES NON-EXECUTIVE DIRECTORS. Connie Matsui Chair of the Board Steven Kelly Compensati Th Douglas Blayney, MD ent, Stanford ¢ of Michi
Slide 25: Company Milestones
Company Milestones Achieved & Near-Term Anticipated Milestones EVENT EXPECTED TIMING ART27.13 Secured Material Data Transfer Agreement and License Option v ART12.12 Discovered cocrystal and filed patent application v ‘ART26.12 Obtained world-wide exclusive license to FABPs target and compounds v Ste
Slide 26: Market and Capital Data
Market and Capital Data Markets: Symbol OTCOB: ARTL Canadian exchange (anticipated 2H 2018) Market Cap « USD $14.3M CDN $18.3M Shares Outstanding «) 12,781,195 Warrants (2) 3,261,195 Options « None Restricted Stock (a 520,000 Fully Diluted 16,562,390 Cash / Cash Equivalents USD $0.525M CDN $0.670M (
Slide 27: Investment Summary
Investor Opportuni Investment Summary Q Three key platforms * Developing best-in-class therapeutics from leading edge science = Portfolio approach to endocannabinoid system (ECS) modulation provides multiple “shots on goal” 6) High-growth sector = Cannabis Biotech/Pharma Market is expected to surpas
Slide 28: Artelo Biosciences Contact
Artel BIOSCIENCES 888 Prospect Street, Suite 210 29 Fitzwilliam Street Upper La Jolla, CA 92037 Dublin 2, Ireland Greg Gorgas (USA) 760.943.1689 Peter O’Brien (IRE) 083 140 6837 gorgas@artelobio.com www.artelobio.com peter@artelobio.com
Artelo Biosciences — Investor Presentation (May 2018) on 6ix